Dasatinib for elderly CML: can reducing dose increase viable patients?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- Dasatinib (Sprycel) was well tolerated and delivered molecular response to most patients aged ≥65 y with chronic myeloid leukemia (CML) at the low dose of ≤20 mg/d.
Why this matters
- Dasatinib is significantly more potent than imatinib in terms of in vitro BCR-ABL inhibition.
- Older patients may not be viable candidates for tyrosine kinase inhibitor (TKI) therapy due to increased risk for grade 3-4 hematologic and nonhematologic toxicities and presence of comorbidities.
- Analysis to investigate the safety and efficacy of low-dose dasatinib in 21 elderly patients with CML in chronic phase (CML-CP); 77% had newly diagnosed CML.
- Initial dose was determined on an individual basis.
- Funding: No...